Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations

AMSTERDAM, December 4 Biopharmaceutical company KiadisPharma announces today that it has successfully completed treatment of thelast patient on its ATIR(TM) phase I/II clinical trial. ATIR(TM), a donorlymphocyte cell based product, is under development to prevent acute Graftversus Host Disease (GvHD) and allow early immune reconstitution following amismatched bone marrow transplantation. Nineteen end stage blood cancerpatients were treated with no cases of grade III/IV acute GvHD occurringwithin the first 100 days after ATIR(TM) infusion, showing the feasibilityand tolerability of the addition of ATIR(TM) in combination with a mismatchedtransplant procedure.

Following scientific advice from the EMEA Kiadis Pharma is preparing toinitiate a multi center multinational pivotal study starting recruitmentearly 2009. In this study the efficacy of ATIR(TM) will be investigated inpatients diagnosed with AML, ALL or MDS eligible for an allogeneic bonemarrow transplantation but for whom no matching donor is available.

"Bone marrow transplantations are often the only treatment option leftfor end-stage blood cancer patients. But too many patients simply do not finda suitable matched donor in time" says Dr. Denis-Claude Roy of theMaisonneuve-Rosemont Hospital in Montreal, the principal investigator on thestudy. "Our study shows a rapid immune reconstitution in transplantedpatients provided with ATIR(TM) treated immune cells from mismatched donors.Without ATIR(TM) treatment this would not be possible because of the highrisk of acute Graft versus Host Disease with mismatched donor immune cells.This is obviously a very hopeful development for a large patient group."

Dr. Manja Bouman, CEO of Kiadis Pharma, says "The results of thisclinical trial are very encouraging and it is another important milestone inthe development of ATIR(TM) as a novel approach which may enable a safe andpotentially life-saving mismatched bone marrow transplantation as a treatmentoption for end-stage blood cancer patients."

For the complete press release please go to: http://www.kiadis.com/news

English release is provided by Kiadis Pharma. Equivalent translations arefrom a third party.

SOURCE Kiadis Pharma

Latest Press Release on General News

Brains Bioceutical Announces the Addition of Industry Veteran John Boshart to its Animal Health Division

VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Today marks a pivotal development for Brains Bioceutical Corp ("Brains Bio"), as it significantly strengthens its Veterin...

Nicklaus Children's Health System, Philips to Provide Innovative Patient and Staff Experience, Helping to Enhance Outcomes for the Smallest of Patients

April 30, 2024 Philips AI-enabled diagnostic and experiential technologies help put patients at ease while empowering staff with faster, high-quality scans and increased diagnostic c...

Cinesteam® Is a Deodorizing Support Tool for Palliative Care

Palliative Care Is a Comprehensive Approach to Long-Term Patient Care. Caregivers Can Use Cinesteam®'s Secondary Dressings to Improve Quality of Life in Palliative Care Settings. FOR...

Philips Delivers First-quarter Results in Line With 2024 Performance Improvement Plan; Resolves the Respironics Personal Injury and Medical Monitoring Litigation in the Us for USD 1.1 Billion

April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4% Comparable order intake -3.8%, mainly due to China USD 1.1 b...

eNeura Achieves Record-Breaking Sales and Announces Notice of Allowance for a New Patent on Prophylactic Treatment of Migraine Headache

Record sales in April accelerating the pathway to profitability New IP will lead the way in changing the way migraine headaches are addressed WEST PALM BEACH, Fla. , April 26, ...